The Healthline report on the Istanbul congress presentation correctly notes that GLP-1 users in a digital program showed larger one-month drops on the Food Noise Questionnaire than behavioral-only participants, yet the coverage underplays the study's core limitations: it is a short-term observational comparison of 417 self-selected adults, not randomized, with no blinding or allocation concealment, and remains unpublished. These design features leave open the possibility that individuals electing GLP-1 therapy already possess different baseline reward sensitivity or motivation. Neuroimaging and pharmacological data supply the missing mechanistic layer. GLP-1 receptors are densely expressed in the hypothalamus, area postrema, and nucleus accumbens; semaglutide and tirzepatide bind these sites, attenuating dopamine release in response to palatable-food cues. A 2022 RCT in Diabetes Care (n=72, crossover design) demonstrated that acute GLP-1 infusion reduced BOLD signal in the ventral striatum during food-picture viewing by 18-24 percent relative to placebo, independent of caloric intake. This central action explains why reductions in intrusive thoughts about ultra-processed foods occur rapidly and why secondary declines in alcohol and nicotine craving are commonly reported. At population scale the effect compounds: sustained lowering of cue reactivity lowers the daily cognitive cost of resisting hyper-palatable environments, converting an otherwise effortful behavioral intervention into a lower-friction default. The original article's emphasis on meal-timing strategies therefore addresses only downstream symptoms while the proximal driver—mesolimbic desensitization—remains pharmacologically targeted.